SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q4 FY20 results · Jan–Mar 2020
SMS Pharmaceuticals reported revenue from operations of ₹96.47 crore (down 7.0% from Q4 FY19) and net profit of ₹6.25 crore (down 3.5% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 96.47 | 103.71 | −7.0% | 80.45 | +19.9% |
| Other income | 3.09 | 0.75 | +312.5% | 0.79 | +289.8% |
| Total income | 99.55 | 104.46 | −4.7% | 81.24 | +22.5% |
| Profit before tax | 8.63 | 8.33 | +3.6% | 12.50 | −30.9% |
| Net profit for the period | 6.25 | 6.48 | −3.5% | 7.50 | −16.7% |
| EPS, basic (₹) | 0.76 | 0.76 | +0.0% | 0.90 | −15.6% |
| Net margin (%) | 6.5 | 6.2 | 9.3 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 96.47 | 103.71 | −7.0% | 80.45 | +19.9% |
| Other income | 3.09 | 0.75 | +312.5% | 0.79 | +289.8% |
| Total income | 99.55 | 104.46 | −4.7% | 81.24 | +22.5% |
| Profit before tax | 8.63 | 8.33 | +3.6% | 12.50 | −30.9% |
| Net profit for the period | 6.25 | 6.48 | −3.5% | 7.50 | −16.7% |
| EPS, basic (₹) | 0.74 | 0.76 | −2.6% | 0.89 | −16.9% |
| Net margin (%) | 6.5 | 6.2 | 9.3 |
Consolidated
- Filed with BSE
- 06 Jun 2020, 15:46 IST
- Board meeting
- 05 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Jun 2020, 15:46 IST
- Board meeting
- 05 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE